{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:35:48Z","timestamp":1765546548513,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00259","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:51:57Z","timestamp":1575028317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center"],"prefix":"10.3389","volume":"6","author":[{"given":"Aheen Faisal","family":"Mohamad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke","family":"Bech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-015-0353-6","article-title":"Pemphigus vulgaris: an evidence-based treatment update","volume":"75","author":"Zhao","year":"2015","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manage"},{"key":"B6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2340\/00015555-1925","article-title":"A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre","volume":"95","author":"Kibsgaard","year":"2015","journal-title":"Acta Dermato Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjd.13350","article-title":"A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone","volume":"172","author":"Hall","year":"2015","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00403-018-1881-1","article-title":"Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?","volume":"311","author":"Balighi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2011","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/ijd.14143","article-title":"Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressorand mitochondrion-protecting drugs","volume":"58","author":"Grando","year":"2019","journal-title":"Int J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000187431","article-title":"Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab","volume":"218","author":"Pfutze","year":"2009","journal-title":"Dermatology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:51:59Z","timestamp":1575028319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":16,"alternative-id":["10.3389\/fmed.2019.00259"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00259","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"article-number":"259"}}